Shenzhen Edge Medical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	455.72	159.99	48.04
Revenue Growth (YoY)	184.83%	233.03%	-
Cost of Revenue	155.06	81.03	43.48
Gross Profit	300.65	78.96	4.56
Selling, General & Admin	225.32	134.72	100.23
Research & Development	185.2	226.25	171.23
Operating Expenses	417.96	362	272.01
Operating Income	-117.31	-283.04	-267.44
Interest Expense	-0.54	-0.86	-0.99
Interest & Investment Income	-	5.22	5.36
Earnings From Equity Investments	-0.09	-	-
Currency Exchange Gain (Loss)	-	-0.12	0.18
Other Non Operating Income (Expenses)	15.97	30.71	3
EBT Excluding Unusual Items	-101.97	-248.09	-259.89
Gain (Loss) on Sale of Investments	13.36	31.02	47.02
Asset Writedown	-	-1.43	-
Pretax Income	-88.61	-218.51	-212.87
Net Income	-88.61	-218.51	-212.87
Net Income to Common	-88.61	-218.51	-212.87
Shares Outstanding (Basic)	354	360	360
Shares Outstanding (Diluted)	354	360	360
Shares Change (YoY)	-1.55%	-	-
EPS (Basic)	-0.25	-0.61	-0.59
EPS (Diluted)	-0.25	-0.61	-0.59
Free Cash Flow	-	-251.03	-381.64
Free Cash Flow Per Share	-	-0.70	-1.06
Gross Margin	65.97%	49.35%	9.49%
Operating Margin	-25.74%	-176.91%	-556.69%
Profit Margin	-19.44%	-136.57%	-443.09%
Free Cash Flow Margin	-	-156.90%	-794.39%
EBITDA	-99.09	-264.82	-259.09
EBITDA Margin	-21.74%	-165.52%	-
D&A For EBITDA	18.22	18.22	8.36
EBIT	-117.31	-283.04	-267.44
EBIT Margin	-25.74%	-176.91%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.